


CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from α PD-L1 and include tissue-selective $\gamma\delta$ T cell activation

Ryan M Reyes, Yilun Deng, Deyi Zhang, Niannian Ji, Neelam Mukherjee, Karen Wheeler, Harshita B Gupta, Alvaro S Padron, Aravind Kancharla, Chenghao Zhang, Myrna G Garcia, Anand VR Kornepati, Onur Boyman, José R Conejo-Garcia, Robert S Svatek, Tyler J Curiel



- IL-2c and α PD-L1 treat primary MB49 and MBT-2 bladder cancer and combine to treat metastatic bladder cancer
- IL-2c mechanisms are distinct from α PD-L1 and differential effects on CD8 and $\gamma\delta$ T cells are present in bladder and lung tumor microenvironments
- IL-2c enhances anti-tumor $\gamma\delta 1$ effects and reduces tumor-promoting $\gamma\delta 17$ effects in bladder